Making clinical trials work the way they should
Clinical trials are how new medicines reach patients. But too often, they're slowed by friction that has nothing to do with science: sites buried in repetitive admin, sponsors chasing updates, and delays that compound before anyone notices.
Double Blind Bio builds AI agents that work inside real workflows, automating the busywork so the people running trials can focus on what actually moves studies forward.
We believe clinical trials should run as smoothly as the science demands. That the people working at research sites deserve tools that respect their time. That sponsors shouldn't have to choose between speed and quality. And that when trials move faster, patients get access to treatments sooner.
We're building the agentic infrastructure to make that real.
We start with sites. Clinical trial sites are where the real work happens and where the most time gets lost. By embedding AI agents directly into site workflows, we create compounding value: better data, faster responses, and a network effect that benefits sponsors too.
We build agents, not dashboards. Another tool to check isn't the answer. Our agents act inside the systems teams already use, handling repetitive work so humans can focus on judgment, relationships, and execution.
We ship fast and learn from customers. Every deployment teaches us something. We iterate quickly, stay close to the people using our products, and let real-world feedback shape what we build next.
We're a team of life sciences and technology experts from Google, Verily, Flatiron Health, and Stanford. We've built clinical data products, healthcare AI systems, and enterprise software—and we started Double Blind Bio because we saw how much time gets lost to work that should be automated.
We're backed by leading venture capital firms including Define Ventures, SignalFire, and Peterson Ventures.
